GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cordlife Group Ltd (SGX:P8A) » Definitions » Debt-to-EBITDA

Cordlife Group (SGX:P8A) Debt-to-EBITDA : 0.47 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Cordlife Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cordlife Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was S$1.81 Mil. Cordlife Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was S$1.69 Mil. Cordlife Group's annualized EBITDA for the quarter that ended in Dec. 2023 was S$7.50 Mil. Cordlife Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cordlife Group's Debt-to-EBITDA or its related term are showing as below:

SGX:P8A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.24   Med: 0.47   Max: 3.65
Current: 0.41

During the past 12 years, the highest Debt-to-EBITDA Ratio of Cordlife Group was 3.65. The lowest was 0.24. And the median was 0.47.

SGX:P8A's Debt-to-EBITDA is ranked better than
82.35% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.775 vs SGX:P8A: 0.41

Cordlife Group Debt-to-EBITDA Historical Data

The historical data trend for Cordlife Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cordlife Group Debt-to-EBITDA Chart

Cordlife Group Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.64 0.28 0.24 0.41

Cordlife Group Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.28 0.21 0.45 0.47

Competitive Comparison of Cordlife Group's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Cordlife Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cordlife Group's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cordlife Group's Debt-to-EBITDA falls into.



Cordlife Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cordlife Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.813 + 1.692) / 8.556
=0.41

Cordlife Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.813 + 1.692) / 7.498
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Cordlife Group  (SGX:P8A) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cordlife Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cordlife Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cordlife Group (SGX:P8A) Business Description

Traded in Other Exchanges
Address
1 Yishun Industrial Street 1, Number 06-01/09, A'Posh Bizhub, Singapore, SGP, 768160
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Cordlife has processing and storage facilities in six key markets across Asia, namely Singapore, Hong Kong, Malaysia, India, Indonesia, and the Philippines. The company has two segments - The Banking segment, comprises cord blood, cord lining, and cord tissue services. The Diagnostics segment comprises Metascreen, which is a non-invasive metabolic screening test specially designed for newborn babies, non-invasive prenatal testing service and Eyescreen, a paediatric eye-screening service.

Cordlife Group (SGX:P8A) Headlines

No Headlines